Group 1 - The core point of the news is that 热景生物 has repurchased approximately 900,000 shares, which is about 0.98% of its total share capital, with a total expenditure of approximately 150 million RMB [1] - The share repurchase was conducted through centralized bidding, with the highest transaction price being 176.79 RMB per share and the lowest at 145.59 RMB per share [1] - As of the announcement date, the market capitalization of 热景生物 is 15.2 billion RMB [2] Group 2 - For the fiscal year 2024, the revenue composition of 热景生物 is primarily from in vitro diagnostic products, accounting for 98.85%, while other businesses contribute 1.15% [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688068 证券简称：热景生物 公告编号：2025-082 北京热景生物技术股份有限公司 关于以集中竞价方式回购股份进展的自愿性披露公告 截至本公告披露日，公司通过股份回购专用证券账户，以集中竞价交易方式 累计回购股份 904,054 股，占公司总股本 92,707,940 股的比例为 0.98%，回购成 交的最高价为 176.79 元/股，最低价为 145.59 元/股，支付的资金总额为人民币 149,955,134.73 元（不含印花税、交易佣金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 北京热景生物技术股份有限公司董事会 2025 年 11 月 24 日 重要内容提 ...

Core Insights - The article highlights the innovative practices of domestic pharmaceutical companies in China, particularly focusing on the advancements made by Realtime Biotech and Tailong Pharmaceutical in the context of the rapidly evolving industry [1][2]. Company Developments - Realtime Biotech, founded by Lin Changqing in 2005, has evolved from an in vitro diagnostic (IVD) company to a biopharmaceutical enterprise, marking a significant transition in its business model [1]. - Tailong Pharmaceutical emphasizes the modernization of traditional Chinese medicine through innovative practices, showcasing the integration of ancient techniques with modern technology in its production processes [1]. Industry Trends - The exploration by Realtime Biotech and Tailong Pharmaceutical reflects the broader trend of innovation within China's biopharmaceutical industry, indicating a shift towards more advanced and diversified medical solutions [2].

Core Viewpoint - The company, as the first IVD listed enterprise on the Sci-Tech Innovation Board, is transitioning from in vitro diagnostics to biopharmaceuticals, aligning with national biomanufacturing strategies and focusing on long-term growth in the biopharmaceutical sector [1][2] Group 1: Industry Trends and Strategic Positioning - Biomanufacturing is recognized as a strategic emerging industry for the next decade, with biopharmaceuticals being a key battleground due to high technical barriers [2] - The company's expansion from in vitro diagnostics to biopharmaceuticals is seen as a natural extension of its core biotechnological competencies, emphasizing the interconnectedness of diagnostic and therapeutic technologies [2] - The company has made significant investments in basic research, publishing multiple papers in top journals and establishing a solid R&D framework [2] Group 2: Innovation and Product Development - The company adheres to the "uniqueness and firstness" principle in its innovation pipeline, focusing on early screening for liver cancer and developing cutting-edge technologies in the field [4][5] - The company’s liver cancer early screening products are widely used in high-risk populations and have been included in expert consensus, contributing to early detection and treatment [4] - The company is also developing the world's first antibody drug for myocardial infarction, which has completed Phase I clinical trials and is preparing for Phase II [5] Group 3: Global Market Expansion - The company has initiated overseas expansion since 2019, achieving over 600 foreign certifications and establishing a presence in Southeast Asia, South Asia, the Middle East, and Latin America [6] - The company aims to provide high-quality, cost-effective medical products to developing countries, enhancing global health equity [6] - The company plans to increase its efforts in overseas market development, leveraging its strong technical capabilities and certification reserves [6] Group 4: Financial Commitment to R&D - The company's R&D investment as a percentage of revenue has been significant, with 24.29% in 2023, 22.18% in 2024, and 23.45% in the first half of 2025 [8]

Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.13% in its stock price, reaching 163.17 CNY per share, with a trading volume of 1.18 billion CNY and a market capitalization of 15.127 billion CNY [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: testing reagents 70.87%, testing instruments 19.79%, others 8.17%, and biological raw materials 1.17% [1] Group 2 - 中航优选领航混合发起A (CASC Optimal Selection Mixed Fund A) has increased its holdings in Hotgen Biotech by 53,100 shares in the third quarter, bringing the total to 290,100 shares, which constitutes 11.14% of the fund's net value, making it the fourth-largest holding [2] - The fund has reported a floating loss of approximately 2.5616 million CNY as of the latest data [2] - The fund manager, 王森 (Wang Sen), has been in charge for 2 years and 55 days, with the fund's total asset size at 2.85 billion CNY. The best return during his tenure is 132.1%, while the worst return is -0.6% [3]

Core Points - The company, Beijing Hotgen Biotech Co., Ltd., has announced a share repurchase plan approved by its board of directors on November 11, 2025 [1][2] - The announcement includes details about the top ten shareholders and the top ten unrestricted shareholders as of the day before the board meeting [1] Group 1: Share Repurchase Plan - The board of directors approved a share repurchase plan via centralized bidding [1] - The details of the repurchase plan were disclosed on November 12, 2025, on the Shanghai Stock Exchange and other designated media [1] Group 2: Shareholder Information - The announcement includes the names, shareholdings, and ownership percentages of the top ten shareholders [1] - It also provides information on the top ten unrestricted shareholders, although specific data is not detailed in the announcement [1]

Investment Rating - The report indicates a positive outlook for the CXO and research services sectors within the pharmaceutical industry, suggesting continued high growth potential [2][3]. Core Insights - The pharmaceutical industry saw a slight decline in sales revenue and a modest increase in net profit for Q3 2025 compared to Q3 2024, with revenue growth rates of -0.1% and net profit growth of 3.0% [2][16]. - The fastest-growing segments in terms of revenue for Q3 2025 were CXO, research services, and pharmaceuticals, while the fastest-growing segments for net profit were research services, CXO, and pharmacies [2][24]. - The report emphasizes the importance of innovative drugs, highlighting that 58 selected innovative drug companies in A-shares experienced a revenue growth of 1.4% and a net profit decline of 4.5% year-on-year for the first three quarters of 2025 [2][28]. - The research services sector showed significant improvement, with a revenue growth of 10.48% and net profit growth of 49.57% in Q3 2025 compared to Q3 2024, indicating a recovery in demand and market conditions [2][3]. Summary by Sections 1. Pharmaceutical Industry - The overall profitability of the pharmaceutical industry showed a slight improvement in Q3 2025, with a net profit margin increase compared to the same period in 2024 [7][17]. 2. Innovative Drugs - Innovative drug companies reported a revenue growth of 3.3% and a net profit decline of 15.0% in Q3 2025, with a focus on companies like Heng Rui Medicine and Rejane Bio [2][28]. 3. Traditional Chinese Medicine - The revenue and net profit growth for traditional Chinese medicine companies remained under pressure, with Q3 2025 showing a revenue decline of 1.1% year-on-year [2][3]. 4. Pharmaceuticals - The pharmaceutical sector experienced a revenue growth of 5.6% and a net profit growth of 12.5% in Q3 2025, indicating a recovery phase [2][3]. 5. Research Services - The research services sector demonstrated strong growth, with a revenue increase of 10.48% and net profit increase of 49.57% in Q3 2025, reflecting a positive market trend [2][3]. 6. Medical Services - Medical services companies faced challenges, with a slight revenue decline of 0.29% in Q3 2025, indicating ongoing pressure from macroeconomic factors [2][3]. 7. Medical Devices - The medical device sector reported a revenue growth of 3.30% in Q3 2025, with expectations for recovery in demand in the coming year [2][3]. 8. Biological Products - The biological products sector continued to face challenges, with a revenue decline of 14.5% in Q3 2025 compared to Q3 2024 [3]. 9. CXO - The CXO sector showed robust growth, with revenue increasing by 11.74% and net profit by 47.47% in Q3 2025, driven by improved market conditions [3]. 10. Raw Materials - The raw materials sector experienced a revenue decline of 8.2% in Q3 2025, influenced by geopolitical factors and reduced domestic demand [3]. 11. Pharmacies - Pharmacy companies reported a revenue growth of 1.9% in Q3 2025, with a focus on profit growth [3]. 12. Pharmaceutical Distribution - The pharmaceutical distribution sector showed a revenue growth of 1.7% in Q3 2025, with increasing industry concentration [3].

证券代码：688068 证券简称：热景生物 公告编号：2025-081 北京热景生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日召开了第四届董事会第六次会议，审议通过了《关于以集中竞价交易方式回购 股份方案的议案》，具体内容详见公司于 2025 年 11 月 12 日在上海证券交易所 网站及公司指定信息披露媒体披露的《关于以集中竞价交易方式回购股份方案的 公告》（公告编号：2025-077）。 北京热景生物技术股份有限公司 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，现将公司董事会公告回购股份决议的前一个交易日（即 2025 年 11 月 11 日）登记在册的前十名股东和前十名无限售条件股东的名称、持股数量和持股比 例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | | 1 | 林长青 | 20,682,487 | 22.31 | | 2 | 周锌 | 5,009,649 | 5.40 | | 3 | 北京热景生物技术股份有限公司 回购专用证券账户 | 3,8 ...

Core Viewpoint - The implementation of the "Guidelines for the Supervision of Listed Companies No. 10 - Market Value Management" has led to a significant increase in the use of various market value management tools by listed companies, including cash dividends, share buybacks, mergers and acquisitions, and equity incentives, to enhance investment value and return to investors [1][2]. Group 1: Market Value Management Tools - Cash dividends and share buybacks have become frequently used tools in the market value management toolbox, with companies encouraged to establish clear mechanisms for share repurchase and to develop and disclose medium- to long-term dividend plans [1][2]. - As of October 31, 2023, 1,195 companies in China's stock market have announced 1,525 share buyback plans for 2025, with a total buyback amount of 92.3 billion yuan, of which 36% was funded by self-owned capital and 26% was for cancellation [2]. - The total cash dividend amount across the market reached 734.9 billion yuan, with 89 companies distributing over 1 billion yuan in dividends within the year [2]. Group 2: Mergers and Acquisitions - The past year has seen a vibrant M&A market, particularly in the "hard technology" sector, with notable cases such as the acquisition of 72.33% of Chip Alliance's shares and the merger of Haiguang Information with Zhongke Shuguang [3]. - State-owned enterprises are also actively engaging in professional integration, exemplified by China Shenhua's plan to consolidate 13 energy companies and Guotai Junan's merger with Haitong Securities [3]. - Policy support has been a key driver for the active M&A market, with various reforms and guidelines aimed at enhancing the efficiency and vitality of mergers and acquisitions [3]. Group 3: Equity Incentives - Equity incentives have been highlighted as a significant market value management tool, with companies encouraged to establish long-term incentive mechanisms [4][5]. - By mid-2023, nearly 3,500 listed companies had implemented equity incentive or employee stock ownership plans, representing 64% of all A-share listed companies [5]. - The recognition of equity incentives as a market value management strategy has deepened, with more companies expected to adopt these tools to enhance long-term value [5].

投资者可于 2025 年 11 月 17 日（星期一）至 11 月 21 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hotgen@ hotgen.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京热景生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 24 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 24 日（星期一） 11:00-12:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：688068 证券简称：热景生物 公告编号：2025-080 北京热景生物技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 会议召开方式：上证路演中心网络互动 三、参加人员 本次投资者说明会以网络互动形式召开 ...